Skip to main content

Advertisement

SpringerLink
Log in

The risk of nephrotic syndrome with non-VEGF inhibitory antineoplastic drugs: from viewpoint of the adverse event reports in Japan

  • Letter to the editor
  • Published:
Clinical and Experimental Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic drugs. Clin J Am Soc Nephrol. 2012;7:1713–21.

    Article  CAS  Google Scholar 

  2. Abbas A, Mirza MM, Ganti AK, Tendulkar K. Renal toxicities of targeted therapies. Target Oncol. 2015;10:487–99.

    Article  Google Scholar 

  3. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data Mining Applications in Engineering and Medicine. London: InTech; 2012. pp. 265–302.

    Google Scholar 

  4. Betton M, Gounant V, Sannier A, Hanouna G, Goujon JM, Brosseau S, Zalcman G, Chemouny JM. Minimal change disease induced by lorlatinib. J Thorac Oncol. 2018;13:e154–e156156.

    Article  CAS  Google Scholar 

  5. Pharmacovigilance Risk Assessment Committee (PRAC) recommendations on signals Adopted at the 10–13 February 2020 PRAC meeting. European Medicines Agency (EMA). Accessed 21 July 2020. www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-10–13-february-2020-prac-meeting_en.pdf.

Download references

Author information

Authors and Affiliations

  1. Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, 1-12-1 Fukumuro, Miyagino-ku, Sendai, Miyagi, 983-8512, Japan

    Kouji Okada, Kensuke Usui & Yoshiteru Watanabe

  2. Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Miyagi, Japan

    Kouji Okada, Kensuke Usui, Daisuke Kikuchi, Masanori Takahashi & Yoshiteru Watanabe

Authors
  1. Kouji Okada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kensuke Usui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daisuke Kikuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masanori Takahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshiteru Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kouji Okada.

Ethics declarations

Conflict of interest

The authors have declared that no conflict of interest exist.

Human and animal rights

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number 2020-4-015), and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Okada, K., Usui, K., Kikuchi, D. et al. The risk of nephrotic syndrome with non-VEGF inhibitory antineoplastic drugs: from viewpoint of the adverse event reports in Japan. Clin Exp Nephrol 25, 97–98 (2021). https://doi.org/10.1007/s10157-020-01957-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10157-020-01957-x

Search

Navigation